ARM & Bioethics
The Alliance for Regenerative Medicine (ARM), the Washington, D.C.-based international coalition advocacy organization representing the gene therapy, cell therapy and tissue engineering sector, applauds the open, multiple-stakeholder discussion on issues related to gene editing that took place during the three-day International Summit on Human Gene Editing. The Summit was held this week at the National Academy of Sciences in Washington, D.C.
ARM encourages and promotes the use of genome editing technologies in somatic (non-reproductive) human cells to durably treat and potentially cure devastating human diseases and conditions. It is our goal to ensure there is no legislative or regulatory action taken that would hinder or delay the use of these techniques (including CRISPR/Cas9, TALEN-based and zinc finger nucleases) in somatic cells, an area of science with much promise that is progressing rapidly.
In response to the statement released by the National Academies, ARM reiterates our position that until the many unresolved safety, ethical and legal concerns surrounding the use of gene editing techniques to manipulate or modify the human germline are adequately addressed, pursuing this line of research is not appropriate at this time. We look forward to actively participating in future policy-shaping discussions related to these important issues.
ARM's Normative Stance, released June 2015
ARM's commentary piece in Nature - "Don't Edit the Human Germ Line," published online March 12, 2015.
- About Us
- Get Involved
- About Regenerative Medicine
- ARM Events
- Committee Meetings
- Regenerative Medicine Industry Events
- Past Events
- ARM in Action
- Committees and Working Groups
- Technology Sections
- European Section
- Patient Resources & Advocacy
- Policy and Government Relations
- Science and Technology
- Regenerative Medicine Promotion Act
- ARM & Bioethics
- ARM Political Action Committee
- Regulatory & Legislative Priorities
- ARM MOUs
- Media Center